Success Metrics

Clinical Success Rate

33.3%

Based on 1 completed trials

Completion Rate

33%(1/3)

Active Trials

0(0%)

Results Posted

300%(3 trials)

Terminated

2(67%)

Phase Distribution

Ph phase_3

67%

Ph phase_2

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 2Efficacy & side effects

1(33.3%)

Phase 3Large-scale testing

2(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(2)

Detailed Status

Terminated2

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

33.3%

Most Advanced

Phase 3

Trials by Phase

Phase 21 (33.3%)

Phase 32 (66.7%)

Trials by Status

terminated267%

completed133%

Recent Activity

0 active trials

Showing 3 of 3

terminatedphase_2

Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease

NCT01731990

terminatedphase_3

Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective

NCT01362608

completedphase_3

Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

NCT00685373

Clinical Trials (3)

Showing 3 of 3 trials

NCT01731990Phase 2

Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease

Terminated

NCT01362608Phase 3

Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective

Terminated

NCT00685373Phase 3

Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3